Pro-angiogenic therapeutics for preeclampsia
Abstract Preeclampsia is a pregnancy-induced hypertensive disorder resulting from abnormal placentation, which causes factors such as sFlt-1 to be released into the maternal circulation. Though anti-hypertensive drugs and magnesium sulfate can be given in an effort to moderate symptoms, the syndrome...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-08-01
|
| Series: | Biology of Sex Differences |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13293-018-0195-5 |
| _version_ | 1811210583911956480 |
|---|---|
| author | Adrian C. Eddy Gene L. Bidwell Eric M. George |
| author_facet | Adrian C. Eddy Gene L. Bidwell Eric M. George |
| author_sort | Adrian C. Eddy |
| collection | DOAJ |
| description | Abstract Preeclampsia is a pregnancy-induced hypertensive disorder resulting from abnormal placentation, which causes factors such as sFlt-1 to be released into the maternal circulation. Though anti-hypertensive drugs and magnesium sulfate can be given in an effort to moderate symptoms, the syndrome is not well controlled. A hallmark characteristic of preeclampsia, especially early-onset preeclampsia, is angiogenic imbalance resulting from an inappropriately upregulated sFlt-1 acting as a decoy receptor binding vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), reducing their bioavailability. Administration of sFlt-1 leads to a preeclamptic phenotype, and several models of preeclampsia also have elevated levels of plasma sFlt-1, demonstrating its role in driving the progression of this disease. Treatment with either VEGF or PlGF has been effective in attenuating hypertension and proteinuria in multiple models of preeclampsia. VEGF, however, may have overdose toxicity risks that have not been observed in PlGF treatment, suggesting that PlGF is a potentially safer therapeutic option. This review discusses angiogenic balance as it relates to preeclampsia and the studies which have been performed in order to alleviate the imbalance driving the maternal syndrome. |
| first_indexed | 2024-04-12T04:58:31Z |
| format | Article |
| id | doaj.art-b66bb0f94c3944f5878e37f4ae11ce7a |
| institution | Directory Open Access Journal |
| issn | 2042-6410 |
| language | English |
| last_indexed | 2024-04-12T04:58:31Z |
| publishDate | 2018-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Biology of Sex Differences |
| spelling | doaj.art-b66bb0f94c3944f5878e37f4ae11ce7a2022-12-22T03:47:03ZengBMCBiology of Sex Differences2042-64102018-08-019111110.1186/s13293-018-0195-5Pro-angiogenic therapeutics for preeclampsiaAdrian C. Eddy0Gene L. Bidwell1Eric M. George2Department of Physiology and BiophysicsDepartment of Cell and Molecular BiologyDepartment of Physiology and BiophysicsAbstract Preeclampsia is a pregnancy-induced hypertensive disorder resulting from abnormal placentation, which causes factors such as sFlt-1 to be released into the maternal circulation. Though anti-hypertensive drugs and magnesium sulfate can be given in an effort to moderate symptoms, the syndrome is not well controlled. A hallmark characteristic of preeclampsia, especially early-onset preeclampsia, is angiogenic imbalance resulting from an inappropriately upregulated sFlt-1 acting as a decoy receptor binding vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), reducing their bioavailability. Administration of sFlt-1 leads to a preeclamptic phenotype, and several models of preeclampsia also have elevated levels of plasma sFlt-1, demonstrating its role in driving the progression of this disease. Treatment with either VEGF or PlGF has been effective in attenuating hypertension and proteinuria in multiple models of preeclampsia. VEGF, however, may have overdose toxicity risks that have not been observed in PlGF treatment, suggesting that PlGF is a potentially safer therapeutic option. This review discusses angiogenic balance as it relates to preeclampsia and the studies which have been performed in order to alleviate the imbalance driving the maternal syndrome.http://link.springer.com/article/10.1186/s13293-018-0195-5PreeclampsiaAngiogenic balancesFlt-1VEGFPlGFTherapeutics |
| spellingShingle | Adrian C. Eddy Gene L. Bidwell Eric M. George Pro-angiogenic therapeutics for preeclampsia Biology of Sex Differences Preeclampsia Angiogenic balance sFlt-1 VEGF PlGF Therapeutics |
| title | Pro-angiogenic therapeutics for preeclampsia |
| title_full | Pro-angiogenic therapeutics for preeclampsia |
| title_fullStr | Pro-angiogenic therapeutics for preeclampsia |
| title_full_unstemmed | Pro-angiogenic therapeutics for preeclampsia |
| title_short | Pro-angiogenic therapeutics for preeclampsia |
| title_sort | pro angiogenic therapeutics for preeclampsia |
| topic | Preeclampsia Angiogenic balance sFlt-1 VEGF PlGF Therapeutics |
| url | http://link.springer.com/article/10.1186/s13293-018-0195-5 |
| work_keys_str_mv | AT adrianceddy proangiogenictherapeuticsforpreeclampsia AT genelbidwell proangiogenictherapeuticsforpreeclampsia AT ericmgeorge proangiogenictherapeuticsforpreeclampsia |